PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshemophilia a
MeSH D006467 - hemophilia a
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D025861:Inherited blood coagulation disorders
29 Companies
2 Drugs
$
Success rate
D020147:Coagulation protein disorders
0 Companies
0 Drugs
Success rate
D006474:Hemorrhagic disorders
1 Company
1 Drug
$
Success rate
D006467: 
Hemophilia a
12 Companies
13 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
BaxaltaRurioctocog alfa pegol Adynovi  2018-01-08   
BayerAntihemophilic factor human recombinant Helixate NexGen  2000-08-04   
Antihemophilic factor human recombinant Iblias  2016-02-18   
Antihemophilic factor human recombinant Kogenate Bayer  2000-08-04   
Antihemophilic factor human recombinant Kovaltry  2016-02-18   
BioMarin PharmaceuticalValoctocogene roxaparvovec Roctavian  2023-06-29 $16.338 M Q3/23-Q3/24 
CSL BehringLonoctocog alfa Afstyla  2017-01-04   
Antihemophilic factor human, Von willebrand factor human Voncento  2013-08-12   
GenentechEmicizumab Hemlibra  2017-11-16   
Laboratoire Francais du Fractionnement et des Biotechnologies S.A.Coagulation factor viia recombinant human Cevenfacta  2022-07-15   
Novo NordiskTuroctocog alfa Esperoct  2019-06-20   
Turoctocog alfa NovoEight  2013-11-13   
Coagulation factor viia recombinant human NovoSeven  1996-02-23   
OctapharmaSimoctocog alfa Nuwiq  2014-07-22   
Simoctocog alfa Vihuma  2017-02-13   
Orphan MedicalEfmoroctocog alfa Elocta  2015-11-18   
PfizerMoroctocog alfa ReFacto  1999-04-13 $230 M Y2023 
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
86%
19/22
Phase 2
91%
20/22
Phase 3
83%
29/35
Approved: 14Overall Success rate: 65%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Baxalta
Rurioctocog alfa pegol,
Benzocaine,
Tifacogin,
Bevifimod,
Diluent,
Rfviia,
Demand
Bayer
Antihemophilic factor human recombinant,
Tifacogin,
Choline alfoscerate,
Befovacimab,
Bevifimod,
Globulin, immune,
Antineoplaston a10,
Rfviia,
Histone-arginine methyltransferase carm1,
Surlorian,
Demand
BioMarin Pharmaceutical
Valoctocogene roxaparvovec,
Bevifimod,
Bos taurus adrenal cortex corticosteroids
CSL Behring
Lonoctocog alfa,
Antihemophilic factor human recombinant,
Antihemophilic factor human,
Von willebrand factor human,
Bevifimod,
Human coagulation factor viii/von willebrand factor complex,
Globulin, immune,
Endocrine,
Optivate,
Rfviia,
Demand
Genentech
Emicizumab,
Lornoxicam,
Aspartame,
Bevifimod,
Nepidermin,
Globulin, immune,
Bos taurus adrenal cortex corticosteroids,
Rfviia,
Demand
Novo Nordisk
Turoctocog alfa,
Coagulation factor viia recombinant human,
Edrecolomab,
Alfacalcidol,
Aspartame,
Bevifimod,
EPTACOG ALFA PEGOL (ACTIVATED),
Globulin, immune,
Rfviia,
Histone-arginine methyltransferase carm1,
Surlorian,
Demand
Octapharma
Simoctocog alfa,
Benzocaine,
Bevifimod,
Human coagulation factor viii/von willebrand factor complex,
Globulin, immune,
Octa101,
Rfviia,
Demand
Orphan Medical
Efmoroctocog alfa,
Benzocaine,
Aspartame,
Bevifimod,
Rfviiifc,
Antineoplaston a10,
Demand
Pfizer
Moroctocog alfa,
Marstacimab,
Tifacogin,
Befovacimab,
Bevifimod,
Edetic acid,
Globulin, immune,
Diluent,
Histone-arginine methyltransferase carm1,
Demand
Roche
Emicizumab,
Lampalizumab,
Bevifimod,
Nepidermin,
Globulin, immune,
NXT007,
Rfviia,
Demand
Takeda
Antihemophilic factor human recombinant,
Aspartame,
Bevifimod,
Globulin, immune,
Rfviia
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use